...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >Drip-and-Ship Thrombolytic Therapy for Acute Ischemic Stroke
【24h】

Drip-and-Ship Thrombolytic Therapy for Acute Ischemic Stroke

机译：急性缺血性卒中的滴灌溶栓治疗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Neuroendovascular therapy is a common treatment for patients with acute ischemic stroke of the anterior circulation who fail to respond to recombinant tissue plasminogen activator. However, although most hospitals can provide recombinant tissue plasminogen activator therapy, many cannot perform neuroendovascular therapy. Thus, use of a drip-and-ship treatment-liaison system allowing recombinant tissue plasminogen activator-treated patients to be transferred to facilities offering neuroendovascular therapy is important. Methods: We retrospectively analyzed 16 drip-and-ship patients transferred to our hospital for additional neuroendovascular therapy after they received intravenous recombinant tissue plasminogen activator at prior hospitals between June 2009 and March 2017. Results: The mean patient age was 68 +/- 17 years. Ten patients had cardiogenic embolism and 6 had atherothrombosis. Additional neuroendovascular therapy was performed in 14 patients. Median National Institute of Health Stroke Scale and diffusion-weighted image-Alberta Stroke Program Early Computed Tomography Scores before recombinant tissue plasminogen activator therapy were 14 and 8, respectively. Occluded or stenotic lesions of the cerebral arteries were detected by magnetic resonance angiography in the internal carotid artery (n = 4), middle cerebral artery (n = 10), and basilar artery (n = 3) (1 patient had tandem lesions). Mean intervals from onset-to-recombinant tissue plasminogen activator, recombinant tissue plasminogen activator-to-our hospital (door), door-to-puncture, and onset-to-recanalization were 166, 65, 32, and 334 minutes, respectively. No patients showed symptomatic intracranial hemorrhage. Conclusions: Magnetic resonance imaging/angiography performed in previous hospitals allows initiation of reperfusion therapy immediately after transfer. Thus, drip-and-ship plus neuroendovascular therapy is a safe and useful system for treatment of patients with acute infarcts.
机译：背景：神经血管治疗是对急性缺血性卒中患者的常见治疗，前循环患者未能应对重组组织纤溶酶原激活剂。然而，尽管大多数医院可以提供重组组织纤溶酶原激活剂疗法，但许多人不能进行神经血管疗法。因此，使用允许重组组织纤溶酶原治疗患者转移到提供神经血管治疗的设施的滴水和船舶治疗联络系统很重要。方法：我们回顾性分析了16例在2009年6月至2017年3月期间接受了先前医院接受静脉注射重组组织纤溶酶原激活因子后转移到我们医院的滴水和船舶的患者。结果：平均患者年龄为68 +/- 17年。十名患者有心源性栓塞，6例患有动脉粥样格管。在14名患者中进行了额外的神经血管疗法。中位数国家健康卒中研究所和扩散加权图像 - 艾伯塔省行程计划早期计算断层摄影分数分别在重组组织纤溶酶原治疗疗法14和8之前。通过内部颈动脉（n = 4），中脑动脉（n = 10），基底动脉（n = 3）（1例患者具有串联病变的基底动脉（n = 4）检测脑动脉的闭塞或狭窄病变。来自初始 - 重组组织纤溶酶原激活剂，重组组织纤溶酶原激活剂 - 我们的医院（门），门对刺穿和开始分别的平均间隔分别为166,65,32和334分钟。没有患者显示出症状颅内出血。结论：在先前医院中进行的磁共振成像/血管造影允许在转移后立即开始再灌注治疗。因此，滴水和船舶加神经养殖疗法是一种用于治疗急性梗塞患者的安全和有用的系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号